温熱腹腔内化学療法を伴う細胞減少手術中の乳酸リンゲル剤と乳酸リンゲル剤を併用した術中 20% アルブミンの使用と乳酸リンゲル剤の併用の有効性: ランダム化非盲検臨床試験のプロトコール (ALBUCHIP)
Remplissage Vasculaire Par de l'ALBUmine Humane 20% + Ringer Lactate comparé au Ringer Lactate Seul Chez Les Patent opérés Par cytoréduction Avec CHimiothérapie Intrapéritonéale hyPerthermique の評価
Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day.
Methods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.
Recruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Information notice and consent form will be delivered. The day before the surgery, anaesthesiologist who will conduct the pre anaesthetic visit will be able to include patients in the study (=inclusion visit). Randomisation will be done at the inclusion visit after information and signature of consent form of voluntary patients. A randomization number will be assigned. The 1:1 randomisation will be centralized via an online interface ensuring secret group assignment, and based on predefined randomisation lists with variable-size permutation blocks, stratified by center. Randomisation will be accomplished using a computer-generated random sequence.
Randomized Open, Blinded endpoint (PROBE) design. This study is a randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.
Intervention
- 20% Albumin + Ringer Lactate group (intervention group) Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
- Control group Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.
Outcome measures The primary outcome will be the Comprehensive Complication Index (CCI score) at day 28 after CRS with HIPEC. Secondary outcomes are mortality at day 28, CCI score at day 7, volume of intra operative and post operative (48h) post operative fluid therapy, cumulated incidence of surgical post operative complications, cumulated incidence of medical post operative complications, need for mechanical ventilation, renal replacement therapy between surgery and day 28, SOFA score variation between pre operative period and 48h after surgery, number of days alive out of intensive care unit and out of hospital until day 28
Sample size calculation To ensure a power of 80%, a number of patients 130 (65 patients by group) will be necessary with a reduction of 13.6 (SD 24) points of the CCI score at day 28 in the intervention group. Because of a risk of neoplastic evolution between anaesthetic consultation and randomisation (10% of early cancellation), a total of 146 patients (73 by group) will be included in the study.
Discussion In summary, ALBUCHIP study will be the first randomized clinical trial assessing efficacy of intraoperative use of 20% albumin combined with Ringer Lactate versus Ringer Lactate during CRS with HIPEC. Results yielded from this study will be helpful for vascular filling during CRS with HIPEC but, thanks to ancillary studies, to improve pathophysiological understanding of this surgery.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Jérôme Lambert, Pr
- 電話番号:+33 142499742
- メール:jerome.lambert@u-paris.fr
研究連絡先のバックアップ
- 名前:Arthur Moreau, Dr
- 電話番号:+33 142499394
- メール:arthur.moreau@aphp.fr
研究場所
-
-
-
Lyon、フランス
- 募集
- Hôpital Lyon Sud Pierre Bénite
-
コンタクト:
- Anne Li
- 電話番号:+33 04 78 86 14 76
- メール:anne.li@chu-lyon.fr
-
Montpellier、フランス
- 募集
- Institut régional du Cancer de Montpellier
-
コンタクト:
- Lana Zoric
- 電話番号:+33 467618538
- メール:Lana.Zoric@icm.unicancer.fr
-
Paris、フランス、75013
- 募集
- La Pitié Salpetriere hospital
-
コンタクト:
- Alexandre Sitbon
- 電話番号:+33 184827399
- メール:alexandre.sitbon@aphp.fr
-
Paris、フランス
- 募集
- Lariboisière hospital
-
コンタクト:
- Nathalie Poirier
- 電話番号:+33 1 49 95 68 43
- メール:nathalie.poirier@aphp.fr
-
Paris、フランス
- 募集
- Saint Louis hospital
-
コンタクト:
- Arthur Moreau
- 電話番号:+33 142499394
- メール:arthur.moreau@aphp.fr
-
Reims、フランス
- 募集
- Robert Debré hospital
-
コンタクト:
- Ezechiel Bankole
- 電話番号:+33 326788801
- メール:ebankole@chu-reims.fr
-
Strasbourg、フランス
- 募集
- Hôpital Hautepierre / UIC ARMO
-
コンタクト:
- Valentina FAITOT
- 電話番号:+33 388116768
- メール:valentina.faitot@chru-strasbourg.fr
-
Villejuif、フランス
- 募集
- Gustave Roussy Institute
-
コンタクト:
- Stéphanie Suria
- 電話番号:+33 142114437
- メール:Stephanie.SURIA@gustaveroussy.fr
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male and female patients aged 18 years old and older
- Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)
- Patient volunteer for the study and provided written informed consent
- Patient affiliated to the French Health Insurance
Exclusion Criteria:
- Adults >75 years old
- Functional status rendering the patient ineligible for cytoreduction with CHIP (ECOG > 2 or Karnofsky index < 75)
- Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)
- Severe preoperative hypoalbuminemia (albuminemia < 20 g/L)
- History of chronic left heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction < 40%)
- Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)
- Significant ascites with preoperative respiratory repercussions
- Uncontrolled diabetes (HbA1c > 8.5%)
- Allergy to exogenous human albumin and its excipients.
- Contraindication to the administration of Ringer's lactate (history of allergy)
- Hyperkalemia > 6.0 mmol/L
- Hypercalcemia (total calcium > 2.60 mmol/L)
- Chronic use of digitalis and hyperkalemic diuretics
- Pregnancy, breastfeeding
- Known preoperative renal failure (GFR < 30 mL/min/1.73m2 or extrarenal purification)
- Recent brain trauma < 6 months (traumatic, ischemic, or hemorrhagic)
- Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable
- Patient deprived of liberty
- Patient under guardianship or curatorship
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:20% Albumin + Ringer Lactate group
Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery. |
Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery. |
|
アクティブコンパレータ:Control group
Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned. |
Ringer lactate |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Comprehensive Complication Index score
時間枠:At day 28
|
The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death |
At day 28
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
術中および術後の輸液療法の量
時間枠:手術から48時間後
|
手術から48時間後
|
|
|
手術後合併症の累積発生率
時間枠:28日目まで
|
28日目まで
|
|
|
集中治療室から出て生存した日数
時間枠:28日目まで
|
28日目まで
|
|
|
退院して生存している日数
時間枠:28日目まで
|
28日目まで
|
|
|
感染性合併症の発症率
時間枠:28日目まで
|
28日目まで
|
|
|
医療合併症の発症率
時間枠:最大28日目まで
|
最大28日目まで
|
|
|
集中治療室における死亡の累積発生率
時間枠:最大28日目まで
|
最大28日目まで
|
|
|
病院内での累積死亡率
時間枠:最大28日目まで
|
最大28日目まで
|
|
|
昇圧薬投与日数
時間枠:最大28日目まで
|
最大28日目まで
|
|
|
アルブミンに対するアレルギー性合併症を有する患者の割合
時間枠:133日目に
|
133日目に
|
|
|
Comprehensive Complication Index score
時間枠:At day 7
|
The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death |
At day 7
|
|
Number of days under mechanical ventilation outside the operating room
時間枠:Up to day 28
|
Between surgery and day 28 |
Up to day 28
|
|
Number of days under renal replacement therapy
時間枠:Up to day 28
|
Between surgery and day 28 |
Up to day 28
|
|
Sequential organ failure assessment (SOFA) score variation
時間枠:48 hours after surgery
|
Between pre operative period and 48h after surgery |
48 hours after surgery
|
|
SOFA score
時間枠:At day 28
|
Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function |
At day 28
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。